	No. of E No. of P					
Subgroup		Chemo	Pembro Hazard Ratio (95% CI)		atio (95% Cl)	P value
Overall		75	94	-+	0.70 (0.47-1.03)	0.07
Age						
	< 70	32/41	22/60		0.56 (0.32-0.97)	0.04
	≥70	30/34	22/34		— 0.96 (0.55-1.68)	0.88
Sex						
	Female	10/15	12/29		0.45 (0.19-1.06)	0.07
	Male	52/60	32/65		0.75 (0.48-1.18)	0.22
Primary site						
	Bladder	28/34	19/44		0.67 (0.37-1.22)	0.19
	Upper tract		25/50		0.69 (0.41-1.16)	0.16
Local lesion	associated with primary					
	No	32/43	20/48		- 0.71 (0.40-1.27)	0.25
	Yes	30/32	24/46		0.67 (0.39-1.15)	0.15
Metastasis	Lymph node					
	No	46/57	29/68		0.75 (0.47-1.21)	0.24
	Yes	16/18	15/26		0.45 (0.21-0.95)	0.037
	Lung					
	No	40/50	27/66		0.62 (0.38-1.02)	0.06
	Yes	2225	17/28		—	0.64
	Liver	50/05	40/00		0 74 (0 40 4 40)	0.40
	No	52/65	40/86		0.74 (0.49-1.12)	0.16
	Yes	10/10	4/8 -		0.53 (0.17-1.71)	0.29
	Visceral	24/44	05/00		0.05 (0.00 4.40)	0.44
	No	34/44	25/62		0.65 (0.39-1.10)	0.11
	Yes	28/31	19/32		— 0.78 (0.43-1.41)	0.42
	Bone	FOICE	27/00		0 74 (0 40 4 42)	0.47
	No	52/65 10/10	37/80		0.74 (0.48-1.13)	0.17
Surgical ran	Yes	10/10	7/14		0.36 (0.12-1.07)	0.07
Surgical ren	noval of primary organ No	26/29	20/33			0.66
	Yes	36/46	20/33		0.60 (0.35-1.01)	0.05
Cis-eligibilit		30/40	24/01		0.60 (0.55-1.01)	0.05
CIS-Eligibilit	y Cisplatin fit	27/31	7/18		- 0.58 (0.25-1.36)	0.21
	Cisplatin unfit	35/44	37/76		0.67 (0.42-1.06)	0.21
First-line	oispiaun unni	33/44	51/10	<b>T</b>	0.07 (0.42-1.06)	0.09
	GC	42/52	29/51		0.76 (0.47-1.24)	0.28
	Gcarbo	15/17	14/36		0.91 (0.44-1.91)	0.28
	GCalbo	13/17	14/30			0.01
			0.125	0.25 0.5 1	2	
			_ <del>(</del>			
			Pembro	lizumab better	Chemotherapy better	

## Supplementary Figure S1. An analysis of overall survival in key subgroups in unweighted population.

The dashed line indicates the rate of overall survival in the entire population. Abbreviations: HR, hazard ratio; CI, confidence interval; GC, gemcitabine plus cisplatin combination chemotherapy; GCarbo, gemcitabine plus carboplatin combination chemotherapy.